While treatment with the anti-PD1 antibody alone tended to increase CD8+ signals, cotreatment with MS-20 and the anti-PD1 antibody further increased CD8+ signals in the tumor microenvironment compared to those in the vehicle control group, as shown by immunohistochemistry (Figure S1h). Here, CD8A is linked to neoplasm.